2015
Local delivery of paclitaxel in the treatment of peripheral arterial disease
Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. European Journal Of Clinical Investigation 2015, 45: 333-345. PMID: 25615282, DOI: 10.1111/eci.12407.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseEndovascular revascularizationArtery diseaseLocal deliveryClinical studiesLocal drug deliveryPeripheral arterial diseasePeripheral vascular diseasePrimary patency rateSystemic adverse effectsUse of paclitaxelLong-term efficacyDrug-Eluting BalloonDrug-eluting stentsTerms of efficacyBrief exposure periodArterial diseaseBalloon angioplastyPatency ratesVascular diseaseBalloon catheterCoated balloonMEDLINE searchStent failureActive drug
2012
Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction
Brener SJ, Cristea E, Lansky AJ, Fahy M, Mehran R, Stone GW. Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction. Circulation Cardiovascular Interventions 2012, 5: 563-569. PMID: 22828707, DOI: 10.1161/circinterventions.112.969022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsAntithrombinsCoronary AngiographyCoronary CirculationDrug-Eluting StentsElectrocardiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionObserver VariationPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionPredictive Value of TestsPrognosisRecombinant ProteinsTubulin ModulatorsConceptsPrimary percutaneous coronary interventionMyocardial blush gradeST-segment elevation myocardial infarctionPercutaneous coronary interventionTIMI flowMyocardial infarctionCoronary interventionMBG 2Post-PCI myocardial blush gradePost-PCI TIMI 3 flowPrimary PCIFinal myocardial blush gradeFinal TIMI flow 0Pre-PCI TIMI flowCore laboratory assessmentFinal TIMI flowRelative prognostic utilityTIMI flow 0Myocardial infarction (TIMI) flowTIMI 3 flowElevation myocardial infarctionImportant prognostic indicatorHarmonizing OutcomesMBG 0Reperfusion marker
2011
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möeckel M, Stone GW. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation 2011, 123: 1745-1756. PMID: 21482968, DOI: 10.1161/circulationaha.110.981688.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsClopidogrelCoronary RestenosisCoronary ThrombosisDrug Therapy, CombinationDrug-Eluting StentsFemaleHeparinHirudinsHumansMaleMetalsMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Aggregation InhibitorsPredictive Value of TestsRecombinant ProteinsRisk FactorsTiclopidineTreatment OutcomeTubulin ModulatorsConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionElevation myocardial infarctionPercutaneous coronary interventionBare metal stentsDrug-eluting stentsStent thrombosisCoronary interventionMyocardial infarctionMetal stentsBivalirudin monotherapyOnly bare-metal stentsAcute Myocardial Infarction trialIIb/IIIa inhibitorsClopidogrel loading dosePotent antiplatelet therapyProbable stent thrombosisAcute stent thrombosisMyocardial Infarction trialAcute myocardial infarctionAntithrombin therapyHarmonizing OutcomesAntiplatelet therapyIndependent predictorsThree-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
Ng VG, Lansky AJ, Hermiller JB, Farhat N, Applegate RJ, Yaqub M, Sood P, Su X, Simonton CA, Sudhir K, Stone GW. Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial). The American Journal Of Cardiology 2011, 107: 841-848. PMID: 21255760, DOI: 10.1016/j.amjcard.2010.10.068.Peer-Reviewed Original ResearchConceptsTarget vessel failure rateSPIRIT III trialXIENCE VIII trialsClinical outcomesLow major adverse cardiac event rateMajor adverse cardiac event ratesAdverse cardiac event ratesMajor adverse cardiac eventsTAXUS paclitaxel-eluting stentAdverse cardiac eventsCardiac event rateCoronary artery lesionsLong-term complicationsPaclitaxel-eluting stentsThree-year resultsLesion revascularizationArtery lesionsCardiac eventsComplication rateStent thrombosisTreatment armsClinical benefitTaxus stentSubset analysisLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
Applegate RJ, Yaqub M, Hermiller JB, Sood P, Yu S, Doostzadeh J, Williams JE, Farhat N, Caputo R, Lansky AJ, Cutlip DE, Sudhir K, Stone GW. Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial). The American Journal Of Cardiology 2011, 107: 833-840. PMID: 21247538, DOI: 10.1016/j.amjcard.2010.10.069.Peer-Reviewed Original ResearchMeSH KeywordsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsLogistic ModelsMaleMiddle AgedPaclitaxelProspective StudiesSingle-Blind MethodSirolimusSurvival RateTreatment OutcomeTubulin ModulatorsUnited StatesConceptsPaclitaxel-eluting stentsMajor adverse cardiovascular eventsSPIRIT III trialAdverse cardiovascular eventsCardiovascular eventsIII trialsPrimary clinical end pointLimited long-term dataTarget lesion revascularizationTarget vessel failureEvent-free survivalClinical end pointsEverolimus-Eluting StentsLong-term safetyLesion revascularizationCardiac deathCoronary arteryMyocardial infarctionSPIRIT IIClinical trialsEfficacy profileUnited States sitesLandmark analysisTerm safetyXIENCE VStrut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction
Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, Stone GW. Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction. Circulation 2011, 123: 274-281. PMID: 21220730, DOI: 10.1161/circulationaha.110.963181.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsOptical coherence tomographyStrut coverageCoherence tomographyBMS lesionsMyocardial infarctionPE lesionsStent strutsMetal stentsPrimary percutaneous coronary interventionAcute Myocardial Infarction trialMyocardial Infarction trialPrespecified end pointElevation myocardial infarctionIndependent core laboratoryPercutaneous coronary interventionStent strut coverageAcute myocardial infarctionSubsequent stent thrombosisDrug-eluting stentsFormal substudyHarmonizing OutcomesStent assignment
2008
Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis
Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kimura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M, Stone GW, Leon MB, Moses JW, Mehran R. Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis. The American Journal Of Cardiology 2008, 101: 801-806. PMID: 18328844, DOI: 10.1016/j.amjcard.2007.10.052.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary StenosisElectrocardiographyFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMyocardial RevascularizationPaclitaxelProspective StudiesSirolimusStentsTreatment OutcomeTubulin ModulatorsUltrasonography, InterventionalConceptsHigh surgical riskMain coronary artery stenosisMajor adverse cardiac eventsUnprotected LMCA stenosisAdverse cardiac eventsCoronary artery stenosisSurgical riskLMCA stenosisCardiac eventsArtery stenosisStent thrombosisMyocardial infarctionBifurcation stenosisUnprotected left main coronary artery stenosisLeft main coronary artery stenosisDrug-eluting stent placementUrgent percutaneous coronary interventionQ-wave myocardial infarctionFeasible therapeutic alternativeOutcomes of patientsPercutaneous coronary interventionPaclitaxel-eluting stentsSingle-stent strategyUnfavorable clinical outcomeSirolimus-eluting stents